The n may vary slightly for the end points at each time point. For Week 24, the n represents the number of subjects randomised at baseline in the subset; lastobservation-carried-forward methodology and non-responder imputation rule were applied to subjects who early escaped at week 16 or had missing value at week 24 for continuous data and binary response, respectively. For week 52, the n represents the number of subjects randomised to APR at baseline in the subset, with an outcome measure at week 52. For week 156, the n represents the number of subjects who were randomised to APR (at baseline, week 16, or Background: PALACE 1, 2, and 3 assessed apremilast (APR) efficacy/safety in subjects with active psoriatic arthritis (PsA) despite prior conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biologics. We report the impact of long-term APR 30 mg BID (APR30) on pre-existing dactylitis and enthesitis in the studies. Methods: Subjects were randomised (1:1:1) to placebo, APR30, or APR 20 mg BID stratified by baseline DMARD use (yes/no). After the 24-week placebo-controlled phase, all subjects received APR and could enroll in long-term follow-up. Data for subjects with pre-existing dactylitis or enthesitis were pooled across PALACE 1-3. Dactylitis count (range: 0-20) was used to assess dactylitis improvement. Evaluation of enthesitis used the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES; range: 0-13). Analyses utilised the lastobservation-carried-forward methodology at week 24 and data as observed for weeks 52 and 156. Results: Among subjects with dactylitis (n ¼ 610) or enthesitis (n ¼ 915) at baseline and !1 post-baseline value, baseline mean dactylitis counts and MASES ranged from 3.2 to 3.4 and 4.4 to 4.8, respectively. At week 24, mean change in dactylitis count was À1.8 (APR30) vs. À1.3 (placebo) (P¼0.0097); more APR30 vs. placebo subjects achieved dactylitis counts¼0. Mean change in MASES was À1.3 (APR30) vs. À0.9 (placebo) (P¼0.0194); more APR30 vs. placebo subjects achieved MASES¼0. The effect on enthesitis was confirmed in the ACTIVE study of APR subjects with 1 prior DMARD using the Gladman Enthesitis Index, focusing on more peripheral sites of activity; significant effect for APR vs. placebo was seen as early as week 2; at week 24, mean change was À1.5 vs. À0.5 (P¼0.0032, mixed-model repeated-measure). Sustained improvements in dactylitis and enthesitis severity were seen with continued APR treatment at week 156 in PALACE 1-3: 79.6% achieved dactylitis count¼0 and mean percent change was À83.6%; 55.0% of APR subjects achieved MASES¼0 and mean percent change was À65.2% (Table 1) . Conclusion: At baseline, 63% of PALACE 1-3 subjects had enthesitis and 42% had dactylitis. With continued treatment, APR30 demonstrated early and long-term benefit ( 156 weeks) in treating dactylitis and enthesitis, including resolution of baseline disease in many subjects. Disclosures: D.D.G. has received consultancies from AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer and UCB, and has received grants/research support from AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer and UCB. A.K. has received grants/research support from Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche and UCB. J.J.G-R. has received consultancies from BMS, Pfizer, Roche, Schering-Plough and UCB and has received grants/research support from Roche and Schering-Plough. J.W. has received consultancies from Abbott, BMS, MSD, Pfizer and UCB and has received grants/research support from Abbott, BMS, MSD, Pfizer and UCB. M.C. has received consultancies from Actelion, BMS and Sanofi-Aventis, and has received grants/research support from Actelion, BMS and Sanofi-Aventis. G.S. has received consultancies from Abbott, Celgene Corporation, Rocheand UCB, and has received grants/research support from Abbott, Celgene Corporation, Roche and UCB. E.L. has received speaker fees from Amgen, Eli Lilly, Novartis and Servier and has received grants/research support from Amgen, Eli Lilly, Novartis and Servier. A.H. is an employee of Celgene Corporation. C.J.E. has received consultancies from Celgene Corporation, Pfizer, Roche and Samsung, and has received speaker fees from Abbott, GSK, Pfizer and Roche. C.J.E has received grants/research support from Celgene Corporation, Pfizer, Roche and Samsung. C.A.B. has received grants/research support from Amgen, BMS, Incyte, Eli Lilly, Merck and Pfizer. P.J.M. has received consultancies from Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Genetech, Janssen, Eli Lilly, Novartis, Pfizer, Roche and UCB, and has received speaker fees from Abbott, Amgen, Biogen Idec, BMS, Genetech, Janssen, Eli Lilly, Pfizer and UCB. P.J.M. has received grants/research support from Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Genetech, Janssen, Eli Lilly, Novartis, Pfizer, Roche and UCB. 
